Press Release

SYNLAB International GmbH
Moosacher Straße 88
80809 Munich
Germany

Munich, 11 February 2026

SYNLAB to further densify its network

SYNLAB, a leader in medical diagnostic services and specialty testing in Europe, has agreed to sell its activities in Slovakia to Unilabs Group. The completion of the transaction is still subject to the approvals of the relevant authorities.

The agreed divestment aligns with SYNLAB's overarching strategy to densify its network by focusing on countries that offer attractive strategic perspectives for the Group's further development. Operations in Slovakia accounted for approximately 0.7% of total Group revenue in 2025.

"Through active portfolio management, we continuously review our activities, the strategic perspectives and future growth potential across our markets. As a result, we have agreed to sell our operations in Slovakia, as we see limited opportunities to further scale up," said Mathieu Floreani, CEO of the SYNLAB Group.

"Efficient capital deployment is a key element of our Group strategy. In line with this strategy, we enhance performance and optimise our network focusing on densification within key countries while diversifying across markets," added Floreani. "We are thankful for the contribution and dedication of our highly skilled SYNLAB colleagues in Slovakia and are confident they will succeed in their new setup."

-- end --

For more information:

Media contact: **Daniel Herbert, FTI Consulting**	daniel.herbert@fticonsulting.com +49 (0) 151 12263834
Investor contact:	ir@synlab.com

About SYNLAB

- SYNLAB Group is a leader in medical diagnostic services and specialty testing in Europe. The Group offers a full range of innovative and reliable medical diagnostics to patients, practising doctors, hospitals and clinics, governments, and corporates.
- Providing the leading level of service within the industry, SYNLAB is the partner of choice for routine and specialty diagnostics in human medicine. The Group continuously innovates medical diagnostic services for the benefit of patients and customers.
- SYNLAB operates in more than 20 countries across four continents and holds leading positions in most markets, regularly reinforcing the strength of its network through a proven acquisition strategy. More than 26,000 employees, including over 2,000 medical experts, contribute every day to the Group's worldwide success.
- SYNLAB performed around 600 million laboratory tests and achieved revenues of €2.62 billion in 2024.
- More information can be found on www.synlab.com